WVE director Adrian Rawcliffe reports Rule 10b5-1 share sale

Rhea-AI Filing Summary

Wave Life Sciences Ltd. (WVE) director Adrian Rawcliffe reported an open-market sale of company stock. On 11/13/2025, he sold 16,115 ordinary shares of Wave Life Sciences at a weighted-average price of $6.79 per share, in multiple transactions executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 5, 2025. After this transaction, the reporting person beneficially owned 12,700 ordinary shares, held directly.

The filing notes that the shares were sold in several trades within a price range of $6.64 to $7.00 per share, and the reporting person has undertaken to provide full details of the number of shares sold at each separate price upon request by the issuer, its security holders, or the SEC staff.

Insider Trade Summary

Net Seller: 16,115 shares ($109,421)

Net Sell 1 txn

Insider Rawcliffe Adrian

Role Director

Sold 16,115 shs ($109K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	16,115	$6.79	$109K

Holdings After Transaction: Ordinary Shares — 12,700 shares (Direct)

Footnotes (1)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.64 to $7.00 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rawcliffe Adrian

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES LTD.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/13/2025		S(1)		16,115	D	$6.79(2)	12,700	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.

2. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.64 to $7.00 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

	/s/ Adrian Rawcliffe	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Wave Life Sciences (WVE) report in this Form 4?

The filing reports that director Adrian Rawcliffe sold 16,115 ordinary shares of Wave Life Sciences Ltd. (WVE) on 11/13/2025 in an open-market transaction.

At what price were the Wave Life Sciences (WVE) shares sold by the director?

The shares were sold at a weighted-average sale price of $6.79 per share, with individual trades occurring in a price range from $6.64 to $7.00 per share.

How many Wave Life Sciences (WVE) shares does the director own after this transaction?

Following the reported sale, Adrian Rawcliffe beneficially owned 12,700 ordinary shares of Wave Life Sciences Ltd., held in direct ownership.

Was the Wave Life Sciences (WVE) insider sale made under a Rule 10b5-1 trading plan?

Yes. The sales disclosed were made pursuant to a Rule 10b5-1 trading plan that the reporting person adopted on August 5, 2025.

Who is the reporting person in this Wave Life Sciences (WVE) Form 4?

The reporting person is Adrian Rawcliffe, who is identified in the filing as a director of Wave Life Sciences Ltd.

Can investors obtain the detailed trade prices for the WVE insider sale?

Yes. The filing states that the reporting person will provide full information on the number of shares sold at each separate price to the issuer, any security holder, or SEC staff upon request.